Applied Therapeutics Stock Plummets 73%. The FDA Delivers This Crushing Blow. - Barron's
1. Applied Therapeutics' stock plunged 73% after FDA declined drug approval. 2. The FDA cited deficiencies in the clinical application of govorestat. 3. The company plans to address FDA concerns moving forward. 4. Previous year-to-date gains of 135% now reversed post announcement. 5. Loss of $730 million in valuation highlights the setback.